Nonoperative, open reduction and internal fixation or primary arthrodesis in the treatment of Lisfranc injuries: A prospective, randomized, multicenter trial - Study protocol by Ponkilainen, Ville T et al.
STUDY PROTOCOL Open Access
Nonoperative, open reduction and internal
fixation or primary arthrodesis in the
treatment of Lisfranc injuries: a prospective,
randomized, multicenter trial – study
protocol
Ville T. Ponkilainen1* , Ville M. Mattila1,2,3, Heikki-Jussi Laine2, Antti Paakkala4, Heikki M. Mäenpää2
and Heidi H. Haapasalo2
Abstract
Background: Lisfranc injuries are known to be rare and often overlooked injuries that can cause long-term
disability and pain when missed or treated incorrectly. The wide variety of Lisfranc injuries ranges from subtle
ligament distensions to open fracture dislocations. The treatment of Lisfranc joint injuries is still controversial and
very little is known about what types of injury can be treated nonoperatively. The current literature provides only
two randomized studies on dislocated Lisfranc injuries. These studies have shown that primary arthrodesis (PA)
leads to a similar or better outcome and results in fewer secondary operations when compared with open
reduction and internal fixation (ORIF) in ligamentous injuries. There have been no previous randomized studies of
the nonoperative versus operative treatment of Lisfranc injuries. Therefore, the purpose of this study is to compare
the operative and nonoperative treatment of non-dislocated Lisfranc injuries and to compare the ORIF and PA
treatment of dislocated Lisfranc injuries.
Methods: This study is a prospective, randomized, national multi-center trial. The trial comprises two strata: Stratum
I compares cast-immobilization versus open reduction and internal fixation (ORIF) treatment of non-dislocated
Lisfranc joint injuries. Stratum II compares PA versus ORIF in the treatment of dislocated injuries of the Lisfranc joint.
The main hypothesis of stratum I is that the nonoperative treatment of non-dislocated Lisfranc injuries achieves a
similar outcome compared with operative treatment (ORIF). The hypothesis of stratum II is that PA of dislocated
Lisfranc injuries yields a similar functional outcome compared with ORIF, but that PA results in fewer secondary
operations than ORIF. The main outcome measure is the American Orthopaedic Foot and Ankle Society (AOFAS)
Midfoot score and the secondary outcome measures are Visual-Analogue-Scale Foot and Ankle (VAS-FA), Visual-
Analogue-Scale (VAS), rate of secondary operations and other treatment-related complications. The results will be
analyzed after the 2-year follow-up period.
Discussion: This publication presents a prospective, randomized, national multi-center trial study protocol. It
provides details of patient flow, randomization, aftercare and methods of analysis of the material and ways to
present and publish the results.
Trial registration: ClinicalTrials.gov identifier: NCT02953067 24.10.2016.
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Background
Named after Jaques Lisfranc, an eighteenth century
surgeon who performed the first foot amputations at the
tarsometatarsal (TMT) joint, the Lisfranc joint is an
anatomic area where a broad spectrum of injuries from
subtle distensions to open fracture dislocations occur [1, 2].
The incidence of Lisfranc injuries is estimated to be
1/55000/year and they are believed to account for
0.2% of all fractures [3, 4]. These figures have, however,
been challenged as up to 24% of Lisfranc injuries are ei-
ther misdiagnosed or overlooked during initial evaluation
[5–7]. Injuries to the Lisfranc joint occur most often dur-
ing the third decade of life and men are 2 to 4 times more
likely to suffer from these injuries than women [8]. Lis-
franc injuries are caused either by direct or indirect forces
to the foot [9]. Indirect injuries are more common and
occur during bending or twisting movements applied to
the midfoot [9]. Injuries caused by direct forces are often
induced by a heavy object falling on top of the foot or by
crush injuries, such as in motor vehicle accidents [6, 7]. A
wide spectrum of injuries to the TMT and interrelated
joints have been recognized, and range from severely dis-
located high-energy open injuries to minor midfoot
sprains suffered during sports activities [10–12].
An untreated or inadequately treated Lisfranc injury
results in multiple late complications, the severity of
which depends on the severity of the primary injury
[13]. The most common complications are painful in-
stability of the joint, malformation and arthritis [5]. All
these complications can lead to remarkable dysfunction
and foot pain [5]. Secondary arthrodesis may be used to
treat these injuries, but the outcome is poorer the longer
the treatment is delayed [14–16]. Therefore, the initial
recognition of these injuries is a crucial step in ensuring
optimal treatment is provided.
Diagnosis and treatment
Fractures of the Lisfranc joint are known to be rare
and are often overlooked [7, 17–19]. Approximately
20 to 24% of these fractures are missed at initial
evaluation [5, 7]. High-energy injuries are often the most
obvious due to traumatic history and very apparent clin-
ical findings [20]. Low-energy injuries, however, are harder
to detect because of less traumatic history and less appar-
ent clinical findings [21]. Typical clinical findings of frac-
ture of the Lisfranc joint are a swollen midfoot, tenderness
and pain in the midfoot during passive movements and
weight-bearing [22], plantar ecchymosis [23] and an
extended space between the first and second toe seen in
x-ray radiographs that is also known as the ‘gap’ sign [24].
Although sensitivity is relatively low when compared
with CT-imaging, primary diagnosis of Lisfranc injuries is
usually based on plain x-ray imaging [7]. False-negative
findings on x-ray radiographs may be the result of
weight-bearing not tolerated due to pain [6]. A typical
finding ‘fleck sign’ in plain x-ray radiographs, an avulsion
of intra-articular bone, is estimated to be detectable in
90% of cases where the dislocation between the first and
second metatarsal is greater than 4 mm [5]. As the radio-
graphic findings of Lisfranc injuries can be subtle, CT is
an important imaging modality in detecting these injuries,
and furthermore serves as a useful tool for preoperative
planning [25, 26]. Although the current literature intro-
duces classifications that provide general characteristics
for Lisfranc injuries, none of the classifications are useful
in predicting treatment or outcome of a Lisfranc injury
[27]. Moreover, the current literature fails to offer a classi-
fication based on computed tomography.
Due to the diversity of injuries, there is no single
evidence-based policy for treating all Lisfranc injuries in
a similar manner [28]. Nowadays, there is strong con-
sensus that in dislocated injuries it is crucial to achieve
exact anatomic reduction and stable internal fixation,
which is best obtained with open reduction and screw fix-
ation (ORIF) [5, 29]. However, even after appropriate
treatment with ORIF, up to 40 to 94% of patients will
develop post-traumatic arthritis [5, 13, 30, 31], necessitat-
ing conversion to an arthrodesis to relieve pain [14–16].
To prevent the need for secondary operations and the
development of post-traumatic arthritis, primary
arthrodesis (PA) is suggested [30, 32–34]. The treatment
of non-dislocated injuries, in turn, is controversial
[29, 35–38]. Some stable injuries might need activity
modification only, but surgery is often recommended for
even minimally displaced injuries [5, 29]. There is general
agreement, however, that poor functional results are com-
monly correlated with a delay in diagnosis or the inad-
equate treatment of unstable or dislocated injuries [19, 27].
Fixation with screws is the primary fixation technique
used to treat dislocated Lisfranc injuries [13, 31]. K-wire
fixation [5, 12, 39, 40] and screw fixation [13, 22, 41, 42]
are both controversial, but the higher failure rates asso-
ciated with K-wire fixation have led to an increase in
screw fixation [13, 43, 44]. Another fixation technique,
dorsal plate fixation, has been reported to produce simi-
lar results as ORIF [45]. An advantage of dorsal plate
fixation is that the plate causes no damage to the articu-
lar surface. However, soft-tissue irritation may be more
prevalent, and second surgery is often needed to remove
the plates [45].
There is, however, no general agreement on what is
the correct nonoperative protocol for treating
non-dislocated Lisfranc injuries. In their review, Myer-
son and Cerrato [11] concluded that if the foot remains
stable in weight-bearing radiographs 2 weeks after the
injury, the injury can be treated with immobilization in a
boot and weight-bearing is permitted as tolerated until
the boot is removed at six to eight weeks. In the study
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by Nunley & Vertullo [29], stable injuries were treated
nonoperatively. Furthermore, it was suggested that treat-
ment begin with a non-weight-bearing cast for 6 weeks.
If the patient is painless at 6 weeks, treatment should
continue with a gradual return to normal function with
a weight-bearing orthosis for the following 4 weeks.
The commonly used postoperative protocol is nearly
identical to nonoperative treatment. In their study, Ly &
Coetzee [30] used a short leg splint for 2 weeks followed
by a short leg cast for four to six weeks. The patients
advanced to full weight-bearing during the following
4 weeks while wearing a prefabricated fracture boot. In
the study by Henning et al. [33], weight-bearing began at
three months with a controlled ankle motion walker.
Interestingly, there are several opinions about postop-
erative implant removal. Some studies suggest routine
screw removal at 8 or 12 weeks [31, 33, 46, 47], while
others prefer routine removal only after the recovery is
complete or only if the screws cause irritation or pain
[48–50]. Ahmad and Jones [51] have suggested the use
of bioabsorbable screws to remove the need for screw
removal. In addition, bioabsorbable screws achieve simi-
lar functional results compared with metal screws.
Evaluation of treatment
Most of the previous studies have used Patient Reported
Outcome Measures (PROMs) to evaluate treatment. The
most common PROM used in Lisfranc injury studies is
the American Orthopaedic Foot and Ankle Society
Midfoot Score (AOFAS) [13, 28, 30, 38, 47]. Other
commonly used PROMs include Visual-Analogue-Scale
Foot and Ankle (VAS-FA) [52] (also validated in the
Finnish language [53]), Visual-Analogue-Scale (VAS)
[28], Short Form 36 (SF-36) [28, 33], Baltimore Painful
Foot Score (PFS) [31], Short Musculoskeletal Function
Assessment (SMFA) [33], long-form Musculoskeletal
Function Assessment (MFA) [13], the Maryland foot
score [47] and activities of daily living (ADL) [47]. In
our study, we decided to use AOFAS because it is the
most commonly used PROM for Lisfranc injuries and
VAS-FA as it is validated in the Finnish language [53].
Previous studies
The literature does not provide any prospective random-
ized controlled studies on the nonoperative versus the
operative treatment of Lisfranc injuries. Current
knowledge is based on a few case-series [35, 37] and
retrospective studies [5, 22, 38]. Nunley and Vertullo
[29] suggested in their series of midfoot sprains in ath-
letes that only totally non-dislocated sprain injuries
should be treated nonoperatively, and that all injuries
where the diastasis between the first and second meta-
tarsal is 2 mm or more would benefit from ORIF. Myer-
son et al. [5] were the first to study the nonoperative
treatment of Lisfranc injury. In their study, only 5 out of
a total of 52 patients were treated nonoperatively, and
these patients received the treatment unintentionally,
due to incorrect diagnosis. Of these five patients, four
resulted in a poor result and one resulted in a fair result.
Curtis et al. [22] organized a retrospective study of the
treatment of 19 athletes with Lisfranc injuries. Only 14
stable injuries were treated nonoperatively. An excellent
functional result was obtained with six patients, a good
result with three patients, a fair result in four and a poor
result with one patient. An excellent result implied the
absence of symptoms and signs; a good result implied
minor symptoms or signs; a fair result implied residual
signs of symptoms with some disability, and a poor re-
sult implied marked symptoms or signs with limitation
of function and a request for further treatment, such as
arthrodesis. The treatment protocol between patients
differed from “none” to “cast for ten weeks”. Crates et al.
[38] studied nonoperative treatment and operative
treatment after the failed nonoperative treatment of sub-
tle Lisfranc injuries in 36 patients. The nonoperative
protocol consisted of 6 weeks of a short leg walking
orthosis and weight-bearing was progressed as tolerated.
Progressed weight-bearing in an orthotic was begun after
boot removal. Nonoperative treatment was successful in
16 patients, and the treatment failed in 20 patients. The
mean AOFAS midfoot score in the successfully
treated patients was 62 (49–72) before treatment and
75 (53–100) after treatment.
There have only been two previous prospective
randomized studies on ORIF vs PA. Ly and Coetzee [30]
randomly assigned 41 patients with ligamentous Lisfranc
injuries to either an ORIF group or a PA group. The PA
group had a slightly better functional outcome (AOFAS
score 88 vs. 69), a higher return to preinjury activity
level (92% vs. 65%), a lower rate of revision surgery and
less pain in the final follow-up. Implant removal due to
prominent or painful screws was performed on 16 of the
20 patients in the ORIF group and on 4 of the 21
patients in the PA group. The implant removal was only
performed due to painful hardware, on average at
6.5 months (range: from five to ten months). Follow-up
radiographs showed loss of correction, increasing de-
formity, and degenerative joint disease in 15 of the 20
patients in the ORIF group and 7 of them required con-
version to an arthrodesis. In the PA group, one patient
had delayed union at seventeen weeks and one patient
required a revision arthrodesis with bone graft. One pa-
tient suffered from a post-traumatic intrinsic compart-
ment syndrome that resulted in claw toes. In the study
by Henning et al. [33], 40 patients with acute Lisfranc
joint fractures or fracture dislocations were randomized
to primary ORIF or PA. A total of 8 patients dropped
out before 3-months follow-up. There was a significantly
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higher rate of secondary surgery in the ORIF group. Sta-
tistically significant differences were not found in phys-
ical functioning with regard to SF-36 or SMFA scores at
any follow-up time interval. In their systematic review
and meta-analysis, Smith et al. [34] concluded that ORIF
has a higher risk of implant removal compared with PA
(risk ratio 0.23 (0.11–0.45) p < 0.001), although there
were no statistically significant differences in revision
surgery, PROMs or non-anatomic alignment. Cochran et
al. [32] organized a retrospective comparative cohort
study on PA versus ORIF in young athletic military
personnel with low-energy Lisfranc injury. In their study,
PA resulted in a faster return to military service, a lower
implant removal rate and better fitness scores after 1 year.
In conclusion, PA seems to result in less secondary
surgery, less implant removal and a faster return to
activity. There is some evidence of a better functional
outcome after arthrodesis, but the result is still contro-
versial. Nevertheless, the current overall evidence
slightly favors arthrodesis as a primary treatment of
dislocated Lisfranc injuries.
Aims of this study
The aim of this two-armed randomized controlled trial
is to I) compare nonoperative treatment with ORIF in
non-dislocated Lisfranc injuries and II) to compare ORIF
with PA in dislocated Lisfranc injuries.
Methods/design
The study is a prospective, randomized, national multi-
center trial. The trial centers are Tampere University
Hospital and Seinäjoki Central Hospital. The trial has
been designed to compare the nonoperative and opera-
tive treatment of Lisfranc injuries. The trial includes two
strata: Stratum I compares nonoperative treatment and
operative treatment with ORIF for non-dislocated
Lisfranc injuries. Stratum II compares ORIF and PA in
dislocated Lisfranc injuries.
The primary outcome in this study is the AOFAS [54]
measured after 6, 12 and 24 months. The secondary
measured outcomes after 6, 12 and 24 months are VAS
[55], VAS-FA [52], number of secondary operations
(implant removal, secondary arthrodesis) and number of
other treatment-related complications.
Hypotheses
Our primary hypotheses in the study are the following:
i) The hypothesis of stratum I is that nonoperative
treatment of non-dislocated Lisfranc injuries yields
better outcome in terms of AOFAS, VAS and
VAS-FA score compared with operative treatment
(ORIF).
ii) The hypothesis of stratum II is that PA of
dislocated Lisfranc injuries yields better functional
outcome in terms of AOFAS, VAS and VAS-FA
score compared with ORIF, and PA results in fewer
secondary operations than ORIF.
The results of both strata will be analyzed and
reported separately.
Patient selection and methods
The study population comprises patients suffering from
acute Lisfranc joint injury (Fig. 1). Clinical suspicion
(pain, swelling, plantar ecchymosis or gap sign) or
typical findings on plain x-ray (‘fleck sign’, avulsion or
fracture) leads to CT where the diagnosis and morph-
ology of the injury is confirmed. Eligible patients are
informed about the study at the emergency room (ER)
by the surgeon on call. The final eligibility of patients
and correct study strata is determined based on CT find-
ings and other medical information and discussion with
the patient by one of the foot and ankle surgeons in the
study group (HH, H-JL, HMM, JJ, OV).
Inclusion criteria
Stratum I (nonoperative treatment vs. ORIF):
 Non-dislocated (< 2 mm) fractures affecting TMT
joints II and III
 And/or Dislocation < 5 mm between medial
cuneiform and base of MT II
 And no fractures affecting TMT joints IV and V
Stratum 2 (ORIF vs. PA):
 Affected joints TMT II - III + any other TMT
 Any dislocation > 2 mm (fracture or TMT joint)
 Dislocation > 5 mm between medial cuneiform and
base of MT II
Exclusion criteria
 Aged under 18 or over 60
 Open fractures
 Extra-articular metatarsal fractures
 Extremely comminuted fractures with bone loss and
poor chance of gaining proper fixation with screws
 Polytrauma patients
 Patients with weak co-operation (dementia,
alcohol use, etc.)
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 Patients with severe circulatory disorder of the
lower limb
 A delay in diagnosis of more than 14 days
 Patients with a previous foot injury or surgery
of the injured foot
 Pregnancy
 Patients who refuse to participate
Randomization
All patients will be randomized by the research
coordinator at Tampere University Hospital who will not
participate in the study. Patients with non-dislocated in-
juries are randomized into a nonoperative or ORIF group.
Patients with dislocated injuries will be randomized into
ORIF or PA groups. Both injury types will be randomized
in blocks of ten. The treatment allocations from the
randomization will be sealed in envelopes which will be
then used and opened in numerical order after patient en-
rolment has been confirmed by the research physician.
The research coordinator will monitor the study flow.
Nonoperative treatment
Nonoperative treatment is conducted with non-weight-
bearing cast-immobilization for 6 weeks. The cast is
changed at 1 and 2 week controls. The cast is removed
at 6 weeks and patients are prescribed a walking boot
for 4 weeks. Weight-bearing with a walking boot is lim-
ited to half-bodyweight for the first 2 weeks and the last
2 weeks as tolerated. At 10 weeks, patients will be
allowed to use their own shoes and walk as tolerated.
Surgical technique
The surgical procedures will be performed by experi-
enced foot and ankle surgeons (HH, H-JL, HM, JJ and
OV). All patients will receive an antibiotic prophylaxis
preoperatively. The operation is performed under tour-
niquet at 280 mmHg to 300 mmHg pressure.
Open reduction and internal fixation
One or two incisions will be made depending on the
location of the injury. Only the affected and instable
Fig. 1 Flow diagram
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TMT joints are fixed. The first incision is made between
MT I-II and the second incision (if necessary) at the
base of MT IV. Open anatomical reduction and screw
fixation of the 2nd metatarsal to the medial cuneiform
bone (‘home run screw’) and affected TMT joints will be
performed with 4.0 cannulated screws (DePuySynthes©,
Stryker©). If TMT IV or V joints are dislocated, after
open reduction of those joints, temporary fixation with
Kirschner-wires will be used (Fig. 2). Fixation will be
performed under fluoroscopic guidance. K-wires will be
cut, bent and left visible on the skin and removed at the
6 week postoperative visit. Wounds will be closed with
dermal sutures. Fixation screws will be removed only if
they cause any symptoms.
Primary arthrodesis
Incisions will be made as described for ORIF. Cartilage
and fibrous tissue will be removed from the affected
TMT joints with a chisel. Fixation for the medial cunei-
form bone to the base of 2nd metatarsal and TMT I-III
will be performed with 4.0 cannulated screws in a simi-
lar manner to ORIF. If TMT IV or V joints are affected,
arthrodesis will not be done, but temporary fixation will
be performed, as described for ORIF.
Postoperative aftercare
Postoperative aftercare is identical to nonoperative treatment
with 6 weeks of non-weight-bearing cast-immobilization
and 4 weeks of walking boot. Stitches are removed, and cast
changed at 2-week visit. The cast and K-wires stabilizing the
TMT IV and/or V joints are removed at 6-week visit.
Thrombosis prophylaxis and analgesic medication is
planned individually.
Follow-up
All follow-up visits will be conducted in the trauma
outpatient clinic of the hospital where the patient was
primarily treated (Table 1). The visits are at 6 weeks,
10 weeks, 6 months, 12 months and 24 months after the
injury. Standing x-ray of the injured foot and VAS score
is obtained during every visit. AOFAS and VAS Foot and
Ankle questionnaires will be completed during the 6, 12
and 24-month visits.
Power analysis
In this trial, the widely recognized AOFAS will be used
as the main outcome measure. The clinically significant
difference in AOFAS has been reported to be 8.36 (SD
11.16) points [56]. Assuming a 10-point difference in the
AOFAS score and a standard deviation of 12 points, the
estimated sample size is 23 patients (delta = 10, sd = 12,
alpha = 0.05, power 0.8). We will assume a 20% drop-out
rate in both groups, and therefore the total patient count
needed for both stratums will be 56 patients. Due to
block randomization in blocks of ten, 60 patients will be
recruited.
Statistical analysis
The baseline characteristics will be reported as mean
(standard deviation), median (quartiles) or proportion.
Study groups will be compared using t-test,
Mann-Whitney U or Fisher’s exact test. Primary
(AOFAS) and secondary outcomes (VAS-FA, VAS, com-
plications, secondary surgery) will be compared at
12 months and 24 months using the Mann-Whitney U
test. The results will be presented with 95% confidence
intervals, and therefore a p-value of < 0.05 will be con-
sidered statistically significant. The data will be analyzed
according to the intention-to-treat principle, assuming
the patients change group during the study. The statis-
tical analysis will be performed with SPSS© version 22.
Fig. 2 Intraoperative view of the screw and K-wire fixation of the
TMT joints
Table 1 Assessments and procedures of the trial
Medical history Radiograph CT VAS AOFAS VAS FA
Baseline X X X
6 weeks X X
10 weeks X X
4 months X X
6 months X X X X
1 year X X X X
2 years X X X X
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Study material
All information will be sent to Tampere University
Hospital and the gathered material will be stored in a
study registry. The registry is protected with passwords
given only to the authors and the secretary of the study
group and the data will be deleted 15 years after the end
of the study.
Ethics
The study protocol and additional papers, including con-
sent form, patient information form and questionnaires
have been approved by the Regional Ethics Committee
of Tampere University Hospital. (Approval number
R11152, 11th November 2011). All participants will pro-
vide a written consent to participate.
Time schedule
The recruitment of patients started in 2011 and it will
be continued until the number of patients achieves the
estimated volume of power analysis. The final results
will be analyzed after the 2-year follow-up period of the
last recruited patient. In October 2017, 51 patients had
been included in the study. The final report will be
published by the end of 2021.
Discussion
This publication presents a prospective, randomized,
national multi-center trial. It gives details of patient flow,
randomization, aftercare and methods of analysis of the
material and ways to present and publish the results.
The limitations of this study are limited patient blinding
due to the nature of the treatment (operative versus
nonoperative) and using a primary outcome measure
(AOFAS) that has not been validated in Finnish. The
strength of this study is that this is the first study to
compare the nonoperative and operative treatment of
Lisfranc joint injuries in a prospective and randomized
study setting with an adequate number of patients. As
the previous literature provides only two contradictory
randomized controlled trials on this matter, the benefits
of this study are to provide evidence-based knowledge
on the treatment of these injuries.
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